CALA - Calithera Biosciences, Inc.
| Previous Close | 4.3000 |
| Open | 4.3000 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 2200 |
| Day's Range | 4.1486 - 4.3100 |
| 52 Week Range | 3.4300 - 6.9000 |
| Volume | 330,239 |
| Avg. Volume | 376,674 |
| Market Cap | 167.951M |
| Beta (3Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7420 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- GlobeNewswire•17 days ago
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib
Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with Pfizer’s CDK 4/6 inhibitor palbociclib, also known as Ibrance®.
- GuruFocus.com•22 days ago
Calithera Biosciences Inc (CALA) PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares
PRESIDENT AND CEO of Calithera Biosciences Inc (NASDAQ:CALA) Susan Molineaux bought 51,600 shares of CALA on 06/25/2019 at an average price of $3.88 a share.
- GlobeNewswire•28 days ago
Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 21, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.
- GlobeNewswire•last month
Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock
SOUTH SAN FRANCISCO, Calif., June 18, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.
- Simply Wall St.•last month
Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain?
While Calithera Biosciences, Inc. (NASDAQ:CALA) shareholders are probably generally happy, the stock hasn't had...
- GlobeNewswire•last month
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. In connection with this offering, Calithera expects to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.
- American City Business Journals•last month
Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more
Looking deeper into a target of a CRISPR deal, a fundraising for more-targeted approach to mental health therapies and more in our Health Care Digest.
- Benzinga•last month
Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy
Calithera, which develops novel small molecule therapies for cancer and other life-threatening diseases, announced positive top-line results from a Phase 2 study dubbed ENTRATA that is evaluating telaglenastat, or CB-839, in combination with the chemotherapy drug everolimus in patients with renal cell carcinoma. The enrollees demonstrated that the evaluated combo treatment doubled the median progress-free survival to 3.8 months compared to 1.9 months for everolimus alone, Calithera said. The risk of disease progression or death was also reduced by 36% in the combo treatment arm.
- GlobeNewswire•last month
Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 Calithera Biosciences Inc Earnings Call
Motley Fool•2 months agoCalithera Biosciences, Inc. (CALA) Q1 2019 Earnings Call Transcript
CALA earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Calithera: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 61 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- Calithera Biosciences,.
- Zacks•3 months ago
Analysts Estimate Calithera (CALA) to Report a Decline in Earnings: What to Look Out for
Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•3 months ago
How Many Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Do Institutions Own?
A look at the shareholders of Calithera Biosciences, Inc. (NASDAQ:CALA) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller compa...
- GlobeNewswire•4 months ago
Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced new preclinical data for the company’s CD73 inhibitor CB-708. The data will be presented today at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. CB-708 is a selective, oral inhibitor of CD73, an enzyme that synthesizes the immunosuppressive agent adenosine and is over-expressed in multiple tumor types.
- Zacks•4 months ago
Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
- GlobeNewswire•4 months ago
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
“The initiation of this clinical trial of telaglenastat in combination with talazoparib marks the first of two clinical trials that will evaluate telaglenastat with approved Pfizer therapeutics as part of this collaboration,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Calithera Biosciences Inc Earnings Call
- GlobeNewswire•4 months ago
Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.
- GlobeNewswire•4 months ago
Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference at 10:40 a.m. ET on Tuesday, March 12, 2019 in Boston. Calithera is headquartered in South San Francisco, California. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
- GlobeNewswire•5 months ago
Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s fourth quarter 2018 financial results will be released on Thursday, March 7, 2019. Company management will host a conference call on Thursday, March 7, 2019 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.
- GlobeNewswire•5 months ago
Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.
- GlobeNewswire•5 months ago
Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D, the company’s founder, president and chief executive officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Thursday, February 28, 2019 in New York City. Calithera is headquartered in South San Francisco, California. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
- GlobeNewswire•5 months ago
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has initiated a Phase 1 clinical trial with CB-280, a novel, orally dosed arginase inhibitor being developed for the treatment of cystic fibrosis (CF). “The initiation of this Phase 1 study with CB-280 marks an important milestone in the advancement of our arginase program,” said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "We believe arginase inhibitors may offer an exciting new therapeutic approach for the treatment of patients with cystic fibrosis, independent of mutational status.
